GSK Notches Phase III Win for Jemperli in Endometrial Cancer

GSK Notches Phase III Win for Jemperli in Endometrial Cancer

Source: 
BioSpace
snippet: 

GSK plans to file for approval of Jemperli in endometrial cancer after the checkpoint inhibitor met its primary endpoint in the Phase III RUBY trial, the company announced Friday.